Latest news with #medicaldiagnostics
Yahoo
a day ago
- Business
- Yahoo
Micromem Technologies Launches Ultra-Sensitive Liquid-Phase Sensor Targeting Disease Biomarkers with Breakthrough Picomolar Detection
Toronto, Ontario and New York, New York--(Newsfile Corp. - August 11, 2025) - Micromem Technologies Inc. (CSE: MRM) (OTCQB: MMTIF) ("Micromem" or the "Company") is pleased to announce the successful development of its liquid-phase nanowire bio-chemical sensor, engineered to detect disease-associated biomarkers at ultra-low concentrations. This innovation marks a critical milestone in the pursuit of more accurate, earlier medical diagnostics. The sensor has demonstrated limit-of-detection performance down to 1 picomolar (pM) and 20mV/decade sensitivity, enabling the identification of inflammatory and pathological biomarkers previously undetectable by conventional methods. The sensor platform is fabricated using standard photolithography processes, making it both cost-effective and scalable for high-volume industrial applications. The initial target analyte is TREM-1 (Triggering Receptor Expressed on Myeloid Cells 1), a key marker known to amplify inflammatory responses and closely associated with a range of diseases including atherosclerosis, cancer, colitis, and fibrosis. Platform Highlights: Ultra-Low Detection Thresholds: Achieves pM-level detection, suitable for early-stage disease monitoring. Broad Diagnostic Utility: Customizable for other critical biomarkers involved in cancer, autoimmune disease, and systemic inflammation. High Signal Clarity: Nanowire-based response delivers real-time, low-noise output with a strong correlation to analyte concentration. Compact and Integratable: Ready for deployment in next-generation lab-on-a-chip, point-of-care, or remote diagnostic devices. Manufactured via conventional photolithography techniques, the platform supports efficient, low-cost production-critical for widespread adoption in clinical and point-of-care diagnostics. Market Relevance With global demand for biomarker diagnostics expected to exceed $100 billion USD by 2030¹, Micromem's platform presents a compelling opportunity for partnerships with biotech, pharmaceutical, and diagnostics companies seeking next-generation sensor technologies. This liquid-phase sensor platform originated from work developed on behalf of the Department of National Defence and is evolving into a commercial diagnostic tool. Micromem is positioning its gas detection technology for integration into industrial and environmental systems through targeted partnerships and pilot initiatives. Precision medicine starts with precision detection. The Company's platform offers the sensitivity, flexibility, and scalability to support a wide array of clinical applications. With the platform now ready for field validation, the Company is seeking co-development and deployment opportunities with strategic industry partners. Micromem is focused on expanding commercial readiness and welcomes pilot deployment opportunities. About Micromem Micromem Technologies Inc. and its subsidiaries, a publicly traded company (CSE: MRM) (OTCQB: MMTIF),develops, and commercializes advanced sensor solutions using proprietary nanotechnology and analyzes specific industry sectors to create intelligent game-changing applications that address unmet market needs. It creates platforms the serve the needs of industries that demand accuracy, durability, and real-time intelligence in detection systems. By leveraging its expertise and experience with sophisticated sensor applications, the Company successfully powers the development and implementation of innovative solutions for oil & gas, utilities, automotive, healthcare, government, information technology, manufacturing and other industries. Visit Safe Harbor Statement This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; continued consumer adoption of digital technology; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer and technological demands; inability to replace significant customers; seasonal nature of our business; and other risks detailed in our filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements. The CSE or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management. ### Listing: OTCQB - Symbol: MMTIFCSE - Symbol: MRMShares issued: 607,024,014SEC File No: 0-26005 Investor Contact: info@ Tel. 416-364-2023 Subscribe to receive News Releases by Email on our website's home page. ¹ According to Grand View Research, the global biomarkers market was valued at USD 59.4 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 13.2% from 2023 to 2030, reaching over USD 110 billion by 2030. To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
05-08-2025
- Business
- Yahoo
Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences: 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 11-12, 2025 Location: Virtual Canaccord Genuity 45th Annual Growth Conference Fireside Chat: August 13, 2025, at 2:30 PM ET Location: Boston, MA The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast. About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-08-2025
- Business
- Yahoo
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results. The webcast will be available at the investor relations section of the Company's website at Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
10-06-2025
- Business
- Globe and Mail
Silicon Photonics Market worth $9.65 Billion by 2030, at a CAGR of 29.5%
"Silicon Photonics Market" The global Silicon Photonics Market Size in terms of revenue is estimated to be worth $2.65 billion in 2025 and is poised to reach $9.65 billion by 2030, growing at a CAGR of 29.5% during the forecast period. The report " Silicon Photonics Market by Product (Transceivers, Variable Optical Attenuators, Switches, Sensors and Cables), Components (Lasers, Modulators, Optical Waveguides, Optical Interconnects, Photodetectors) - Global Forecast to 2030" The global silicon photonics industry was valued at USD 2.65 billion in 2025 and is projected to reach USD 9.65 billion by 2030, growing at a CAGR of 29.5% from 2025 to 2030. One of the rising market drivers for silicon photonics is building quantum communication and computing systems that demand ultra-high-speed, ultra-secure transmission of optical data-making scalable photonic integrated circuits a prerequisite and photonic circuits precise for achieving this requirement. Another frontier driver is increasing wearables-based medical diagnostics in which silicon photonics facilitates wearable, non-invasive biosensors to monitor the patient's condition on a constant basis, triggering widespread adoption of personalized healthcare devices. Both industries unlock new frontiers beyond the legacy data and telecom markets and extend silicon photonics into leading-edge applications. Download PDF Brochure @ Data Center and HPC segment are expected to have the largest market share during the forecast period. The HPC and data center segment is likely to hold the highest market size in the Silicon Photonics Industry due to the growing demand for high-speed, energy-efficient data transmission on the back of cloud computing, AI, and big data analytics. Silicon photonics technology allows faster processing and lower latency in hyperscale data centers, addressing the need to process high volumes of data. Market participants can ride this growth by creating high-technology optical interconnects and transceivers designed for high-bandwidth applications. In addition, progress in photonic integrated circuits (PICs) and co-packaged optics can enhance scalability and performance. Investment in edge computing and 5G infrastructure solutions allows firms to benefit further from the increasing demand for dynamic bandwidth allocation and low-latency systems. Strategic partnerships with cloud providers and telecommunication operators will also allow market participants to acquire a significant portion of this rapidly growing segment. The optical waveguide segment is expected to witness the highest CAGR during the forecast period. The segment of optical waveguides is likely to have the highest CAGR over the forecast period due to growing demand for high-speed data transmission and developments in photonic technology. Optical waveguides play a very important role in facilitating the efficient carrying of signals in telecom networks, data centers, AR/VR devices, and medical imaging devices. Industry participants will be able to surf on this wave by developing new waveguide solutions tailored to 5G networks, edge computing, and PICs with advanced photonic integrated circuits. The encouragement of quantum communications technologies and optical computing with AI-based technology also provides a rich area for better waveguide solutions in consumer electronics, and thin and light infrastructure designs can also ride on the increased need for high-speed optical components with smaller sizes. Strategic partnerships with telecom companies and technology leaders will also contribute to gaining market share in this fast-growing sector. The US is projected to hold the largest market share in North America during the forecast period. The US will lead the North American silicon photonics industry in terms of the highest market value by 2030 on account of its very superior technological infrastructure and heavy research and development expenditures. Its availability of key industry giants such as Intel, IBM, and Cisco, in addition to favorable government policies such as collaborations with AIM Photonics, stimulates innovation in high-speed optical communication equipment for data centers, HPC, and 5G networks market players will be able to leverage this dominance by making sure they focus on the development of innovative photonic integrated circuits (PICs) and co-packaged optics that will be for high-bandwidth applications. Also, collaboration with cloud service providers and telecom companies in the US will enable companies to tap into hyperscale data centers and newer communication technologies. By aligning with government-supported programs and investing in state-of-the-art manufacturing plants, companies can further make their place within this burgeoning market sector. The major players in the Silicon Photonics Companies are Cisco Systems, Inc. (US), Intel Corporation (US), MACOM (US), GlobalFoundries Inc. (US), Lumentum Operations LLC (US), Marvell (US), Coherent Corporation (US), IBM (US), and STMicroelectronics (Switzerland). About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook.
Arab News
03-06-2025
- Business
- Arab News
Makkah Health Cluster brings AI-powered healthcare platform ‘iSelfie' to region
The Makkah Health Cluster has signed a cooperation agreement with Canadian company AIZTech, which specializes in AI-powered medical diagnostics, to deploy the iSelfie platform across its facilities, including King Abdullah Medical City and several major hospitals in Makkah. The signing ceremony was attended by Jean-Philippe Linteau, ambassador of Canada to Saudi Arabia; Dr. Mubarak Al-Mulhem, director general of healthcare at the Ministry of Investment; and Dr. Hatim Al-Omari, CEO of the Makkah Health Cluster, which oversees more than 10 hospitals in the city. Also present were Dr. Adel Tash, CEO of King Abdullah Medical City, and Tarek Sultan, vice chairman of Agility. The agreement was signed by Al-Omari and Mohamed Sheta, CEO of AIZTech. This marks the first agreement of its kind in the Middle East, allowing patients to benefit from instant health assessments using AI through a short facial video, with no additional hardware required. The iSelfie platform analyzes the video to extract key health metrics including blood pressure, heart rate, blood oxygen saturation, and respiratory rate. The platform will be integrated into the patient-facing screens within hospital facilities and will be used with the assistance of medical staff. Al-Omari said: 'We are proud to be the first in the Kingdom and the region to adopt this advanced technology, which reflects our ongoing commitment to harnessing the latest digital solutions to enhance diagnostic efficiency and accelerate patient care. This step marks a qualitative leap toward a more advanced and innovative healthcare system, aligned with the goals of Saudi Vision 2030.' Tash added: 'In line with the spirit of digital transformation and the ambitious Saudi Vision 2030, we are pleased to launch this innovative AI-powered technology in Makkah. This launch is backed by a pivotal study conducted across the Kingdom, where the technology showed promising results when compared with 1,021 cases diagnosed using traditional medical devices. We are committed to expanding access to these advanced tools to benefit the wider community in the region.' Sheta said: 'We are honored to collaborate with one of the Kingdom's leading public healthcare institutions. This agreement is a clear indicator of the growing trust in AI-powered healthcare solutions and reinforces our belief that remote, non-invasive early diagnostics will be a core part of healthcare's future.' Ambassador Linteau said: 'Digital health innovation is gaining momentum in Canada, and Saudi Arabia is a market that is open to early adoption of innovation in the health sector.' He also expressed hope that the platform will achieve remarkable success in the early detection of health conditions in patients. The iSelfie platform has proven its effectiveness through clinical trials conducted in Saudi Arabia, the US, Canada, and Brazil, including a national study supported by the Saudi Food and Drug Authority. Results showed that the platform provides accurate readings comparable to traditional medical devices, with the added benefits of rapid assessment, accessibility, and cost efficiency. This collaboration aligns with the goals of Saudi Vision 2030, which places innovation and digital transformation at the heart of healthcare development by improving the quality of life, promoting preventive care, and expanding access to modern medical services.
